Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M20-186 LTE of elsubrutinib and upadacitinib (alone or in combination) in SLE
jRCT2031210119Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of elsubrutinib, upadacitinib and ABBV-599 in systemic lupus erythematosus (SLE) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Number of participants with adverse events. Started Apr 2021; status: completed.
02
Drugs
elsubrutinibupadacitinibABBV-599
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2031210119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210119.